100% Quality Guarantee
PhD-Level Technical Support
Human CD276 Recombinant Protein (N-His)
Key Features

Human CD276 Recombinant Protein (N-His) (GXRP02435)

SKU GXRP02435
Product Type Recombinant Protein
Species Human
Expression System E. coli
Tag N-His
$458 - $2,412

Request a formal quotation

A PDF quote with its own quote number, ready for your purchasing office to raise a PO against. Back within 4 working hours, from a PhD scientist — not an autoresponder.

  • PO-ready PDFQuote number, VAT, Incoterms
  • Volume pricing appliedDiscounts from 2 kits up
  • Valid 30 daysPrices held while you get sign-off
Anything we should know? optional

No account needed. We use your details only to prepare and send this quote. If it's urgent, say so in the box and we'll come back the same working day.

Global Shipping: 80+ Countries
White Glove Service: Available upon request
Batch Consistency: Contact Sales
Distributors: 60+ Countries

Description

system_update_altDatasheetsystem_update_altMSDS

Human CD276 Recombinant Protein (N-His)

Human CD276 Recombinant Protein (N-His) is a recombinant protein expressed in E. coli, spanning Thr47-Ser219, with an N-terminal His tag. Predicted molecular weight: 20.97 kDa. Purity: >90% as determined by SDS-PAGE. Supplied lyophilized from a solution in PBS pH 7.4, 0.02% NLS, 1 mM EDTA, 4% Trehalose, 1% Mannitol. Applications: ELISA, immunogen, SDS-PAGE and Western blot. CD276 antigen (B7-H3) is a ~57 kDa protein. May participate in the regulation of T-cell-mediated immune response. For research use only.

May play a protective role in tumor cells by inhibiting natural-killer mediated cell lysis as well as a role of marker for detection of neuroblastoma cells. May be involved in the development of acute and chronic transplant rejection and in the regulation of lymphocytic activity at mucosal surfaces. Could also play a key role in providing the placenta and fetus with a suitable immunological environment throughout pregnancy. Both isoform 1 and isoform 2 appear to be redundant in their ability to modulate CD4 T-cell responses. CD276 is the therapeutic target of omburtamab (clinical).

View AllClose

0 Reviews

0
Based on 0 reviews

No reviews yet. Be the first to share your experience!

View AllClose